Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.54%0700.HK-5.72%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.12%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.22%0857.HK-0.49%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-2.31%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.61%AUDUSD-1.43%AUDCAD-0.96%EURAUD+0.95%AUDCHF-0.94%GBPAUD+0.87%AUDNZD-0.82%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.70%CHFJPY-0.67%CADJPY-0.66%NZDUSD-0.61%GBPUSD-0.55%AUDSGD-0.54%USDCHF+0.52%AUDDKK-0.50%EURUSD-0.50%USDCAD+0.49%AUDNOK-0.43%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.31%NZDMXN+0.29%GBPMXN-0.28%USDZAR+0.25%USDTHB+0.22%USDTRY+0.21%USDJPY-0.20%EURZAR+0.20%GBPZAR+0.16%USDILS+0.16%NZDCAD-0.15%CHFNOK+0.14%NZDCHF-0.13%CHFSEK+0.12%USDNOK+0.12%USDCNH-0.12%EURNZD+0.12%NOKJPY-0.10%USDSEK+0.10%USDPLN+0.10%EURCNH-0.08%GBPCAD-0.08%GBPSGD-0.07%PLNJPY-0.07%GBPNZD+0.07%EURGBP+0.06%EURNOK+0.06%EURHKD-0.06%USDDKK+0.05%EURSEK+0.05%EURPLN+0.04%EURSGD-0.04%EURCZK+0.04%USDCOP-0.04%CHFSGD+0.03%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%EURCAD-0.02%USDSGD+0.01%USDHKD-0.01%NZDSGD+0.01%EURDKK0.00%UKOIL+1.12%USOIL+0.92%GAGUSD+0.68%XAGUSD+0.68%COTTON+0.66%XNGUSD-0.65%GAUUSD+0.55%XAUUSD+0.55%HG1+0.43%W1-0.23%C1-0.17%XPTUSD+0.03%BTCUSD-3.25%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.15%XMRUSDT-1.51%DOGEUSD+55.95%LINKUSD-3.05%XLMUSD-3.56%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.39%SUIUSD-2.95%TONUSD+59.18%HBARUSDT-4.76%TAOUSDT-2.95%AAVEUSD-3.05%ONDOUSDT-5.00%ICPUSDT-2.61%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-4.99%ATOMUSDT-2.54%INJUSDT-6.72%STXUSDT-2.75%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-3.86%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.14%OPUSDT-2.63%IOTAUSDT-2.39%POLUSDT-1.66%WIFUSDT-2.98%AXSUSDT-2.47%EOSUSDT-4.38%IMXUSDT-3.36%FARTCOINUSDT-5.56%GALAUSDT-2.38%DYDXUSDT-2.58%ORDIUSDT-2.73%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.54%0700.HK-5.72%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.12%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.22%0857.HK-0.49%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-2.31%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.61%AUDUSD-1.43%AUDCAD-0.96%EURAUD+0.95%AUDCHF-0.94%GBPAUD+0.87%AUDNZD-0.82%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.70%CHFJPY-0.67%CADJPY-0.66%NZDUSD-0.61%GBPUSD-0.55%AUDSGD-0.54%USDCHF+0.52%AUDDKK-0.50%EURUSD-0.50%USDCAD+0.49%AUDNOK-0.43%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.31%NZDMXN+0.29%GBPMXN-0.28%USDZAR+0.25%USDTHB+0.22%USDTRY+0.21%USDJPY-0.20%EURZAR+0.20%GBPZAR+0.16%USDILS+0.16%NZDCAD-0.15%CHFNOK+0.14%NZDCHF-0.13%CHFSEK+0.12%USDNOK+0.12%USDCNH-0.12%EURNZD+0.12%NOKJPY-0.10%USDSEK+0.10%USDPLN+0.10%EURCNH-0.08%GBPCAD-0.08%GBPSGD-0.07%PLNJPY-0.07%GBPNZD+0.07%EURGBP+0.06%EURNOK+0.06%EURHKD-0.06%USDDKK+0.05%EURSEK+0.05%EURPLN+0.04%EURSGD-0.04%EURCZK+0.04%USDCOP-0.04%CHFSGD+0.03%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%EURCAD-0.02%USDSGD+0.01%USDHKD-0.01%NZDSGD+0.01%EURDKK0.00%UKOIL+1.12%USOIL+0.92%GAGUSD+0.68%XAGUSD+0.68%COTTON+0.66%XNGUSD-0.65%GAUUSD+0.55%XAUUSD+0.55%HG1+0.43%W1-0.23%C1-0.17%XPTUSD+0.03%BTCUSD-3.25%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.15%XMRUSDT-1.51%DOGEUSD+55.95%LINKUSD-3.05%XLMUSD-3.56%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.39%SUIUSD-2.95%TONUSD+59.18%HBARUSDT-4.76%TAOUSDT-2.95%AAVEUSD-3.05%ONDOUSDT-5.00%ICPUSDT-2.61%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-4.99%ATOMUSDT-2.54%INJUSDT-6.72%STXUSDT-2.75%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-3.86%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.14%OPUSDT-2.63%IOTAUSDT-2.39%POLUSDT-1.66%WIFUSDT-2.98%AXSUSDT-2.47%EOSUSDT-4.38%IMXUSDT-3.36%FARTCOINUSDT-5.56%GALAUSDT-2.38%DYDXUSDT-2.58%ORDIUSDT-2.73%NOTUSDT+0.86%RONINUSDT-2.92%

FDA clears Regeneron’s Livsayis for gMG

NEWS

November 19, 2026 at 00:21 UTC

5 min read
Unbranded prescription box and leaflet on pharmacy counter illustrating new FDA-cleared gMG therapy

Key Points

  • 01FDA approves Regeneron’s Livsayis for AChR-positive gMG in adults
  • 02First and only siRNA therapy for gMG with quarterly SC dosing
  • 03Phase 3 NIMBLE trial showed significant MG-ADL and QMG gains
  • 04Drug carries boxed meningococcal warning and REMS restriction

FDA approval of Livsayis for generalized myasthenia gravis

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) for the treatment of adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive. Livsayis is a complement component 5 (C5)-directed small interfering RNA therapy and is the first and only approved siRNA treatment for this form of gMG. It is also the only FDA-approved gMG medicine administered subcutaneously four times per year, once every three months.

The newly approved indication targets the predominant form of gMG, in which abnormal anti-AChR antibodies activate the complement system including C5. In the United States, generalized myasthenia gravis affects approximately 85,000 people, many of whom continue to experience suboptimal disease control or high treatment burden despite existing options.

Clinical evidence from the Phase 3 NIMBLE trial

FDA approval is based on results from the Phase 3 NIMBLE trial, described as the largest global interventional gMG trial conducted to date. In this randomized, double-blind, placebo-controlled study, adults with AChR-antibody-positive gMG were assigned to one of four regimens: Livsayis every three months, Livsayis plus a C5-inhibiting monoclonal antibody every four weeks, the monoclonal antibody alone every four weeks, or placebo every four weeks, with background immunosuppressants allowed.

On the primary endpoint, change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at 24 weeks, Livsayis achieved a least squares mean improvement of 4.5 points compared with 2.2 points on placebo, a placebo-adjusted improvement of 2.3 points with a p-value of 0.0005. A clinically meaningful MG-ADL response of at least 3 points at week 24 occurred in 76.6% of Livsayis-treated patients versus 44.1% on placebo.

For the key secondary endpoint, change in Quantitative Myasthenia Gravis (QMG) total score at 24 weeks, Livsayis demonstrated a 4.2-point improvement compared with 1.5 points on placebo, corresponding to a placebo-adjusted gain of 2.8 points with a p-value of 0.0015. At least a 5-point QMG improvement at week 24 was seen in 48.4% of patients receiving Livsayis and 19.0% of those on placebo. Clinically meaningful MG-ADL benefit of 2.5 points emerged as early as two weeks after starting treatment, with improvements deepening over time and sustained through the dosing interval.

Mechanism of action and dosing profile

Livsayis is a complement C5-directed siRNA that degrades the messenger RNA encoding C5, thereby blocking C5 production, lowering circulating C5 levels and inhibiting terminal complement activation. This mechanism targets a key driver of AChR-positive gMG by intervening upstream at the level of hepatic C5 production rather than binding circulating C5 protein directly.

The therapy is administered as a subcutaneous injection once every three months, providing four-times-a-year dosing. Among complement-targeted options for gMG, this quarterly schedule is noted as the least frequent dosing within the class, and disease control in NIMBLE was maintained through the end of each three-month dosing interval without evidence of waning efficacy over 24 weeks.

Safety profile and REMS requirements

Prescribing information for Livsayis includes a boxed warning for serious, life-threatening or fatal meningococcal infections. The medicine may lower the ability of the immune system to fight certain infections, and it is contraindicated in patients with an active meningococcal infection. Patients must complete meningococcal vaccination at least two weeks before the first dose, or receive both vaccination and antibiotics if treatment must begin sooner.

Livsayis is available only through the Livsayis Risk Evaluation and Mitigation Strategy program. Before prescribing, healthcare providers must enroll in the REMS, counsel patients on meningococcal risk, ensure appropriate vaccination, and provide a Patient Safety Card that patients are instructed to carry during treatment and for 12 months after the last dose. The most common adverse reactions, occurring in at least 5% of treated patients and more often than with placebo, are injection site reactions, viral infections and urinary tract infections.

Strategic importance for Regeneron and next steps

Livsayis is Regeneron’s first approved medicine in neurology and its first approved siRNA therapy. The company develops, manufactures and commercializes Livsayis under a worldwide licensing agreement with Alnylam Pharmaceuticals. Regeneron characterizes the approval as a meaningful step for its neuroscience pipeline focused on serious neurological diseases.

Outside the United States, a regulatory submission for Livsayis for gMG is under review in the European Union, with a decision anticipated in the second half of 2027, and additional submissions are planned in other markets including Japan. Regeneron also offers its myRARE program to support patients and healthcare providers with product information, insurance benefit verification and information on potential financial assistance for Livsayis.

Key Takeaways

  • 01Livsayis introduces an siRNA-based complement C5 inhibitor to gMG care, with quarterly subcutaneous dosing and sustained 24-week efficacy in a large Phase 3 trial.
  • 02Clinically meaningful improvements in both MG-ADL and QMG scores, coupled with early onset of benefit, position Livsayis as a potent option for AChR-antibody-positive adults.
  • 03The therapy’s boxed meningococcal warning and REMS requirements underscore the need to balance efficacy with infection risk management and pre-treatment vaccination.
  • 04For Regeneron, Livsayis marks entry into neurology and siRNA therapeutics, while parallel EU and planned Japanese filings point to an expanding global strategy.

FDA clears Regeneron’s Livsayis for gMG | Trading Dashboard